DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,828,440 B2 Bodick Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,828,440 B2 Bodick Et Al USOO8828440B2 (12) United States Patent (10) Patent No.: US 8,828,440 B2 Bodick et al. (45) Date of Patent: Sep. 9, 2014 (54) CORTICOSTEROIDS FOR THE TREATMENT OTHER PUBLICATIONS OF JOINT PAIN Anderson et al. “Biodegradation and Biocompatibility of PLA and (75) Inventors: Neil Bodick, Boston, MA (US); Robert PLGA Microspheres.” Adv. Drug Deliv Rev. 28(1997):5-24. C. Blanks, Auburndale, MA (US); Ayral et al. “Synovitis: A Potential Predictive Factor of Structural Anjali Kumar, Belmont, MA (US); Progression of Medial Tibiofemoral Knee Osteoarthritis—Results of Michael D. Clayman, Gloucester, MA a 1 Year Longitudinal Arthroscopic Study in 422 Patients.” (US); Mark Moran, Orinda, CA (US) OsteoArth. Cartilage. 13(2005):361-367. Bouissou et al. “Poly(lactic-co-glycolic acid) Microspheres.” Poly (73) Assignee: Flexion Therapeutics, Inc., Burlington, mers in Drug Delivery. Chapter 7(2006): 81-99. Cleek et al. “Microparticles of Poly(DL-lactic-co-glycolic acid)/ MA (US) poly(ethylene glycol) Blends for Controlled Drug Delivery.” J. Con (*) Notice: Subject to any disclaimer, the term of this trol. Relase. 48(1997): 259-268. Coopman et al. “Identification of Cross-Reaction Patterns in Allergic patent is extended or adjusted under 35 Contact Dermatitis from Topical Corticosteroids.” Br: J. Dermatol. U.S.C. 154(b) by 0 days. 121 (1989):27-34. Derendorfetal. “Clinical PKPDModelling as a Tool in Drug Devel (21) Appl. No.: 13/422,994 opment of Corticosteroids.” Int. J. Clin. Pharmacol. Ther. 35.10(1997):481-488. (22) Filed: Mar 16, 2012 Derendorf et al. “Pharmacokinetics and Pharmacodynamics of Glucocorticoid Suspensions After Intra-Articular Administration.” (65) Prior Publication Data Clin. Pharmacol. Ther: 39.3(1986):313-317. US 2012/O288534 A1 Nov. 15, 2012 Eckstein et al. “Magnetic Resonance Imaging (MRI) of Articular Cartilage in Knee Osteoarthritis (OA): Morphological Assessment.” OsteoArth. Cartilage. 14(2006):A46-A75. Related U.S. Application Data Foti et al. "Contact Allergy to Topical Corticosteroids: Update and (63) Continuation of application No. 13/198,168, filed on Review on Cross-Sensitization.” Recent Pat. Inflamm. Allergy Drug Aug. 4, 2011, now abandoned. Discov. 3.1(2009):33-39. Habib. "Systemic Effects of Intra-Articular Corticosteroids.” Clin. (60) Provisional application No. 61/370,666, filed on Aug. Rheumatol. 28.7(2009):749-756. 4, 2010. Hepper et al. “The Efficacy and Duration of Intra-Articular Corticosteroid Injection for Knee Osteoarthritis: A Systematic (51) Int. Cl. Review of Level I Studies.” J. Am. Acad. Orthop. Surg. A6 IK 9/14 (2006.01) 17.10(2009):638-646. A 6LX 9/50 (2006.01) Hill et al. “Synovitis Detected on Magnetic Resonance Imaging and A6 IK3I/56 (2006.01) its Relation to Pain and Cartilage Loss in Knee Osteoarthritis.” Ann. A 6LX3/573 (2006.01) Rheum. Dis. 66(2007): 1599-1603. A6 IK9/00 (2006.01) Houetal. “In Situ Gelling Hydrogels Incorporating Microparticles as A6 IK 9/16 (2006.01) Drug Delivery Carriers for Regenerative Medicine.” J. Pharm. Sci. (52) U.S. Cl. 97.9(2008):3972-3980. CPC ............. A61 K9/1647 (2013.01); A61 K3I/573 Kirwan et al. “Effects of Glucocorticoids on Radiological Progres (2013.01); A61 K9/0024 (2013.01); A61 K sion in Rheumatoid Arthritis.” Cochrane Database Syst. Rev. (2009). 9/0019 (2013.01); A61 K9/1641 (2013.01); (Continued) A61 K9/1694 (2013.01) USPC ............................ 424/489: 424/497: 514/181 (58) Field of Classification Search Primary Examiner — David J Blanchard None Assistant Examiner — Tigabu Kassa See application file for complete search history. (74) Attorney, Agent, or Firm — Cooley LLP (56) References Cited (57) ABSTRACT U.S. PATENT DOCUMENTS Corticosteroid microparticle formulations are provided for 4.293,539 A 10/1981 Ludwig et al. use for treating pain, including pain caused by inflammatory 7,261,529 B2 8/2007 Persyn et al. 7,758,778 B2 7/2010 Persyn et al. diseases such as osteoarthritis or rheumatoid arthritis, and for 2004/O105821 A1* 6/2004 Bernstein et al. ............... 424/46 slowing, arresting or reversing structural damage to tissues 2005/OO31549 A1 2/2005 Quay et al. caused by an inflammatory disease, for example damage to 2007/0053990 A1 3/2007 Persyn et al. articular and/or peri-articular tissues caused by osteoarthritis 2007,0264.343 A1 11/2007 Bernstein et al. or rheumatoid arthritis. Corticosteroid microparticle formu 2008/0248122 A1 10/2008 Rashba-Step et al. 2008/0317805 A1 12/2008 McKay et al. lations are administered locally as a Sustained release dosage 2009, OO35253 A1 2/2009 Wright et al. form (with or without an immediate release component) that 2009, O123546 A1 5, 2009 Ashton et al. results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production. FOREIGN PATENT DOCUMENTS WO WO-95.13799 A1 5, 1995 10 Claims, 30 Drawing Sheets US 8,828.440 B2 Page 2 (56) References Cited Morlocket al. “Erythropoietin Loaded Microspheres Prepared from Biodegradable LPLG-PEO-LPLG Triblock Copolymers: Protein OTHER PUBLICATIONS Stabilization and in-vitro Release Properties.” J. Control. Release. 56.1-3(1998): 105-115. La Rochelle et al. “Recovery of the Hypothalamic-Pituitary-Adrenal Rojas et al. “Microdialysis of Triamcinolone Acetonide in Rat Muscle.” J. Pharm. Sci. 92.2(2003):394-397. (HPA) Axis in Patients with Rheumatic Diseases Receiving Low van den Berg et al. “Synovial Mediators of Cartilage Damage and Dose Prednisone.” Am. J. Med. 95(1993):258-264. Repair in Osteoarthritis.” Osteoarthritis. Brandt et al., eds. Oxford: Lo et al. "Bone Marrow Lesions in the Knee are Associated with Oxford University Press. 7.2.3 (2003): 147-155. Increased Local Bone Density.” Arth. Rheum. 52.9(2005):2814 Yeh. “The Stability of Insulin in Biodegradable Microparticles Based 2821. on Blends of Lactide Polymers and Polyethylene Glycol.” J. Lo et al. “The Ratio of Medial to Lateral Tibial Plateau Bone Mineral Microencapsul. 17.6(2000):743-756. Density and Compartment-Specific Tibiofemoral Osteoarthritis.” Zentner et al. "Biodegradable Block Copolymers for Delivery of OsteoArth. Cartilage. 14(2006):984-990. Proteins and Water-Insoluble Drugs.” J. Control. Release. Meibohm et al. “Mechanism-Based PK/PD Model for the 72(2001):203-215. Lymphocytopenia Induced by Endogenous and Exogenous Corticosteroids.” Int. J. Clin. Pharmacol. Ther: 37.8(1999):367-376. * cited by examiner U.S. Patent Sep. 9, 2014 Sheet 1 of 30 US 8,828,440 B2 FIG. 1 tra-articular COf Cetration - - - - - - - - - - - - - - - - - - - - - - intra-articular concentration required for efficacy Concentration in plasma associated with PA axis suppression L. H. - - - - - - - - - - - - - - - - - e Concentration in piasma ise post in tra articiar injection of sistaired release corticosteroid FIG. 2 TCA40mg EC50 (ng/mL) U.S. Patent Sep. 9, 2014 Sheet 2 of 30 US 8,828,440 B2 FIG. 3 -BPA 7mg EC50 (ng/mL) ---TCA 40 mg EC50 (ng/mL) -THCA 20 mg EC50 (ng/mL) 1 5 1.O O 50 1OO 150 2OO 250 300 350 4OO Time (h) U.S. Patent Sep. 9, 2014 Sheet 3 of 30 US 8,828,440 B2 0'09 88segg. A &:3SEgg, U.S. Patent Sep. 9, 2014 Sheet 4 of 30 US 8,828,440 B2 U.S. Patent Sep. 9, 2014 Sheet 5 Of 30 US 8,828,440 B2 O?000||O O| ----^ O\-|0.08 |0.07 |0.02 8:35 egg: A U.S. Patent Sep. 9, 2014 Sheet 6 of 30 US 8,828,440 B2 FIG. 5 100 . ; 90 m. 3. 80 70 --------------------------------0----------------------------------- 60 o S$ 50 $ 40 -/-.-0-25%. TCAPLGA75:25 30 20 s 10 O O 10 2O 3O Days FIG. 6 25%. TCAPLGA 75:25 -0-Adjusted Dose (mg/day) - - - 5% COrtisol Inhibition - - - -35% COrtisol Inhibition DOSe - - - - - - - - - - - - 40% COrtisol Inhibition DOSe H - H - H - H - H - - - - a 50% COrtisol Inhibition DOSe 10 15 2O 25 3O U.S. Patent Sep. 9, 2014 Sheet 7 Of 30 US 8,828,440 B2 FIG. 7 25%. TCAPLGA 75:25 -0- Adjusted Dose (mg/day) - - - 5% COrtisOl Inhibition - - - - 35% COrtisol Inhibition DOSe 40% COrtisol Inhibition DOSe 50% COrtisO Inhibition DOSe FIG. 8 100 90 8O 70 1 5060 1 40 / -0-25%. TCAPLGA 75:25 30 10 7 10 20 3O DayS U.S. Patent Sep. 9, 2014 Sheet 8 of 30 US 8,828,440 B2 FIG. 9 25% TCAPLGA 75:25 8.O 7.O -0-Adjusted DOSe (mg/day) 6.O - - -5% COrtisol 5.O Inhibition 4.0 - - - -35% COrtisol 3.O Inhibition DOSe 2.0 40% COrtisol Inhibition DOSe 1.O 50% COrtisOl O.O Inhibition DOSe -10 0 FIG. 10 25%. TCAPLGA 75:25 -0-Adjusted Dose (mg/day) - - - 5% COrtisol Inhibition - - - -35% COrtisol Inhibition DOSe 40% COrtisol Inhibition DOSe 50% COrtisol Inhibition DOSe U.S. Patent Sep. 9, 2014 Sheet 9 Of 30 US 8,828,440 B2 FIG 11 25%. TCA 5% PEG 1450/PLGA 75:25 1 OO 90 8O 70 60 - 25% TCA 5% PEG 50 145O/PLGA75:25 40 30 20 10 z 20 Days FIG. 12 25%. TCA 10% PEG 335OIPLGA 75:25 1 OO 90 8O 70 - 25%TCA 10%PEG 60 335O/PLGA75:25 50 40 30 2O 10 - 3O Days U.S. Patent Sep. 9, 2014 Sheet 10 of 30 US 8,828,440 B2 FIG. 13 25%. TCA 5% PEG 1450/PLGA 75:25 -0- Adjusted Dose (mg/day) - - - 5% COrtisol Inhibition - - - -35% COrtisol Inhibition DOSe 40% COrtisol Inhibition DOSe 50% COrtisol O 10 2O 30 Inhibition DOSe -1.0 - FIG. 14 25% TCA 10% PEG 3350/PLGA 75:25 7.O 6.O M -0- Adjusted(mg/day) Dose 5.0 | \ - - - 5% COrtisO 4.O Inhibition 3.0 ...Y - - - -35% COrtisol -S Inhibition DOSe 2.01.0 seaseO 40%Inhibition COrtisol DOSe 0.0-R F FEF RF FEF - F.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al
    US 20080317805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 McKay et al. (43) Pub. Date: Dec. 25, 2008 (54) LOCALLY ADMINISTRATED LOW DOSES Publication Classification OF CORTICOSTEROIDS (51) Int. Cl. A6II 3/566 (2006.01) (76) Inventors: William F. McKay, Memphis, TN A6II 3/56 (2006.01) (US); John Myers Zanella, A6IR 9/00 (2006.01) Cordova, TN (US); Christopher M. A6IP 25/04 (2006.01) Hobot, Tonka Bay, MN (US) (52) U.S. Cl. .......... 424/422:514/169; 514/179; 514/180 (57) ABSTRACT Correspondence Address: This invention provides for using a locally delivered low dose Medtronic Spinal and Biologics of a corticosteroid to treat pain caused by any inflammatory Attn: Noreen Johnson - IP Legal Department disease including sciatica, herniated disc, Stenosis, mylopa 2600 Sofamor Danek Drive thy, low back pain, facet pain, osteoarthritis, rheumatoid Memphis, TN38132 (US) arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural (21) Appl. No.: 11/765,040 space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug (22) Filed: Jun. 19, 2007 depot. E Day 7 8 Day 14 El Day 21 3OO 2OO OO OO Control Dexamethasone DexamethasOne Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr 0.0032ng/hr 0.016 ng/hr 0.08 ng/hr Patent Application Publication Dec. 25, 2008 Sheet 1 of 2 US 2008/0317805 A1 900 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 80.0 - 7OO – 6OO - 5OO - E Day 7 EDay 14 40.0 - : El Day 21 2OO - OO = OO – Dexamethasone Dexamethasone Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr O.OO32ng/hr O.016 ng/hr 0.08 nghr Patent Application Publication Dec.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Ep 0173478 A1
    Patentamt JEuropaischesJ European Patent Office @ Publication number: 0173 478 ^ ^ Office europeen des brevets EUROPEAN PATENT APPLICATION Application number: 85305552.3 © 'nt. CI ": A 61 K 35/78, A 61 K 31 /57 Dateof filing: 05.08.85 (A61K35/78, 31 :57),(A61K31/57, 31 :23, 31 :20) @ Priority: 15.08.84 GB 8420771 @ Applicant: EFAMOL LIMITED, Efamol House Woodbridge Meadows, Guildford Surrey GU1 1BA (GB) @ Date of publication of application: 05.03.86 @ Bulletin 86/10 efamol House woodbridge meadows, Guildford Surrey GU1 1BA (GB) @ Representative : Caro, William Egerton et al, J. MILLER & @ Designated Contracting States: AT BE CH DE FR GB IT CO. Lincoln House 296-302 High Holborn, London LILUNLSE WC1V7JH(GB) @ Treatment of skin disorders. A topical composition for skin treatment contains an anti- inflammatory glucocorticoid in combination with an essential fatty acid (EFA) of the n-6 or n-3 series or equivalent poly- unsaturated fatty acid, as such or in the form of a physio- logically acceptable derivative convertible in the body thereto. FIELD OF INVENTION The invention relates to compositions of y-linolenic acid and related materials with anti-inflammatory glucocorticoids and to the treatment of inflammatory skin disorders with them. BACKGROUND AND EXPLANATION OF INVENTION Much interest has been shown in recent years in essential fatty acid metabolism, especially in its relation to prosta- glandin (PG) metabolism and in particular to the balance of 1-series and 2-series PGs in the body. The main dietary essential fatty acid (EFA) utilised in the fully healthy human body is linoleic acid, but the Δ6- desaturase that converts it to the next acid in the n-6 series, namely y-linoleic acid (GLA) is at a low level of activity in many conditions.
    [Show full text]
  • General Agreement on Tariffs Andtrade
    RESTRICTED GENERAL AGREEMENT TAR/W/87/Rev.1 16 June 1994 ON TARIFFS AND TRADE Limited Distribution (94-1266) Committee on Tariff Concessions HARMONIZED COMMODITY DESCRIPTION AND CODING SYSTEM (Harmonized System) Classification of INN Substances Revision The following communication has been received from the Nomenclature and Classification Directorate of the Customs Co-operation Council in Brussels. On 25 May 1993, we sent you a list of the INN substances whose classification had been discussed and decided by the Harmonized System Committee. At the time, we informed you that the classification of two substances, clobenoside and meclofenoxate, would be decided later. Furthermore, for some of the chemicals given in that list, one of the contracting parties had entered a reservation and the Harmonized System Committee therefore reconsidered its earlier decision in those cases. I am therefore sending you herewith a revised complete list of the classification decisions of the INN substances. In this revised list, two substances have been added and the classifications of two have been revised as explained below: (a) Addition Classification of clobenoside, (subheading 2940.00) and meclofenoxate (subheading 2922.19). (b) Amendment Etafedrine and moxidentin have now been reclassified in subheadings 2939.40 and 2932.29 respectively. The list of INN substances reproduced hereafter is available only in English. TAR/W/87/Rev. 1 Page 2 Classification of INN Substances Agreed by the Harmonized System Committee in April 1993 Revision Description HS Code
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
    [Show full text]